Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Mylan Inc

Market Cap 19.19B 16.58B 15.27B 14.3B 26.8B 1,824B 27.21B 180B 70.32B 888B 72.03B 70.49B 3,074B P/E Ratio 2026 *
60.3x
P/E Ratio 2027 * 26.1x
Enterprise Value 31.38B 27.1B 24.97B 23.38B 43.81B 2,983B 44.49B 295B 115B 1,452B 118B 115B 5,027B EV / Sales 2026 *
2.12x
EV / Sales 2027 * 2.01x
Free-Float
92.11%
Yield 2026 *
3.09%
Yield 2027 * 3.17%
Manager TitleAgeSince
Chief Executive Officer 63 01/04/2023
Director of Finance/CFO 59 08/05/2026
Chief Tech/Sci/R&D Officer - 15/12/2023
Director TitleAgeSince
Director/Board Member 78 16/11/2020
Director/Board Member 78 16/11/2020
Director/Board Member 62 16/11/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.18%-2.55%+38.67%+146.70% 1,010B
-1.56%+2.32%+53.03%+45.08% 580B
-2.21%-0.69%+16.06%+63.01% 402B
-0.24%0.00%+21.28%+19.14% 330B
-1.09%+2.54%+24.85%+33.14% 281B
-1.78%-4.36%+21.96%+12.90% 280B
-0.24%+5.20%-42.55%-48.18% 197B
+0.07%+2.60%+20.02%+55.28% 192B
-0.21%-2.86%+12.28%+57.52% 156B
Average -0.84%+0.84%+18.40%+42.73% 380.97B
Weighted average by Cap. -0.88%+1.04%+27.36%+66.80%

Financials

2026 *2027 *
Net sales 14.77B 12.76B 11.76B 11.01B 20.63B 1,404B 20.95B 139B 54.13B 684B 55.45B 54.27B 2,367B 15.04B 12.99B 11.97B 11.2B 21B 1,429B 21.32B 141B 55.1B 696B 56.44B 55.23B 2,409B
Net income 13M 11.23M 10.34M 9.68M 18.15M 1.24B 18.43M 122M 47.62M 601M 48.78M 47.74M 2.08B 498M 430M 396M 371M 695M 47.29B 705M 4.68B 1.82B 23.02B 1.87B 1.83B 79.7B
Net Debt 12.19B 10.53B 9.7B 9.08B 17.01B 1,158B 17.28B 115B 44.65B 564B 45.74B 44.76B 1,952B 11.03B 9.53B 8.78B 8.22B 15.4B 1,048B 15.64B 104B 40.42B 510B 41.4B 40.52B 1,767B
Logo Mylan Inc
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!